Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptansc1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16	JAN 02	STN pricing information for 2008 now available
NEWS 17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19	JAN 28	MARPAT searching enhanced
NEWS 20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23	FEB 08	STN Express, Version 8.3, now available
NEWS 24	FEB 20	PCI now available as a replacement to DPCI
NEWS 25	FEB 25	IFIREF reloaded with enhancements
NEWS 26	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 27	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:40:05 ON 07 MAR 2008

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:40:17 ON 07 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2008 HIGHEST RN 1006950-27-1
DICTIONARY FILE UPDATES: 6 MAR 2008 HIGHEST RN 1006950-27-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10579564.str





chain nodes :
7 14 15 16
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 20 21 22 23
chain bonds :
5-7 7-8 14-15 14-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 10-20 11-12 11-23 20-21
21-22 22-23
exact/norm bonds :
5-7 7-8 8-9 8-12 9-10 11-12 14-15 14-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-20 11-23 20-21 21-22 22-23

G1:[*1],[*2]

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 20:Atom 21:Atom 22:Atom
23:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 [@1],[@2]
G2 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s sss sam l1
SAMPLE SEARCH INITIATED 18:40:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5129 TO ITERATE

39.0% PROCESSED 2000 ITERATIONS 3 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 98286 TO 106874
PROJECTED ANSWERS: 3 TO 319

L2 3 SEA SSS SAM L1

=> d scan

L2 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Propanedioic acid, compd. with 2-(2-benzofuranyl)-N-butyl-2-(4-chlorophenyl)-1,3-dioxolane-4-methanamine (9CI)
MF C22 H24 Cl N O3 . x C3 H4 O4

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pyrrolidine, 1-[[2-(2-benzofuranyl)-2-phenyl-1,3-dioxolan-4-yl]methyl]-
MF C22 H23 N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzofuran, 2-[4-(bromomethyl)-2-phenyl-1,3-dioxolan-2-yl]-, cis- (9CI)
MF C18 H15 Br O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>
Uploading C:\Program Files\Stnexp\Queries\10579564A.str





chain nodes :
7 14 15 16
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 20 21 22 23
ring/chain nodes :
25 26
chain bonds :
5-7 7-8 13-25 13-26 14-15 14-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 10-20 11-12 11-23 20-21
21-22 22-23
exact/norm bonds :
5-7 7-8 8-9 8-12 9-10 11-12 13-25 13-26 14-15 14-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-20 11-23 20-21 21-22 22-23

G1:[*1],[*2]

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 20:Atom 21:Atom 22:Atom
23:Atom 25:CLASS
26:CLASS

L3   STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3   STR





G1 [@1],[@2]
G2 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s sss sam l3
SAMPLE SEARCH INITIATED 18:44:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   5129 TO ITERATE

 39.0% PROCESSED   2000 ITERATIONS   0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 98286 TO   106874
PROJECTED ANSWERS: 0 TO   0

L4   0 SEA SSS SAM L3

=> s sss full l3
FULL SEARCH INITIATED 18:48:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   99103 TO ITERATE

100.0% PROCESSED 99103 ITERATIONS 107 ANSWERS
SEARCH TIME: 00.00.03

L5 107 SEA SSS FUL L3

=> save l5 LU10579564/A
ANSWER SET L5 HAS BEEN SAVED AS 'LU10579564/A'

=> d scan

L5 107 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3-Pentanol, 3-[[4-[1-ethyl-1-(6-methoxybenzo[b]thien-2-yl)propyl]-2-methylphenoxy]methyl]-
MF C27 H36 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L5 107 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN L-Alanine, N-[[2-[1-ethyl-1-[4-(2-ethyl-2-hydroxybutoxy)-3-methylphenyl]propyl]benzo[b]thien-6-yl]carbonyl]-
MF C30 H39 N O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 107 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzo[b]thiophene-5-carboxylic acid, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-
MF C27 H34 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>
Uploading C:\Program Files\Stnexp\Queries\10579564B.str





chain nodes :
7 14 15 16
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 20 21 22 23
ring/chain nodes :
24 25
chain bonds :
5-7 7-8 13-24 13-25 14-15 14-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 10-20 11-12 11-23 20-21
21-22 22-23
exact/norm bonds :
5-7 7-8 8-9 8-12 9-10 11-12 14-15 14-16
exact bonds :
13-24 13-25
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-20 11-23 20-21 21-22 22-23

G1:[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 20:Atom 21:Atom 22:Atom

23:Atom 24:CLASS
25:CLASS

L6   STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6   STR





G1 [@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

=> s sss l6 subset=l5 sam
SAMPLE SUBSET SEARCH INITIATED 18:51:42 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -   0 TO ITERATE

100.0% PROCESSED   0 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):   ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):   0 TO   0
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):   0 TO   0

L7   0 SEA SUB=L5 SSS SAM L6

=> s sss l6 subset=l5 full
FULL SUBSET SEARCH INITIATED 18:51:50 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -   38 TO ITERATE

100.0% PROCESSED   38 ITERATIONS   38 ANSWERS
SEARCH TIME: 00.00.01

L8   38 SEA SUB=L5 SSS FUL L6

=> d scan

L8   38 ANSWERS   REGISTRY COPYRIGHT 2008 ACS on STN
IN   Methanesulfonic acid, trifluoro-, 2-[1-ethyl-1-[4-(2-ethyl-2-

hydroxybutoxy)-3-methylphenyl]propyl]benzo[b]thiophene-6-yl ester (9CI)
MF C27 H33 F3 O5 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l5 not l8
L9 69 L5 NOT L8

=> d scan

L9 69 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 6-Benzofurancarboxylic acid, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-, methyl ester
MF C28 H36 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	230.12	230.33

FILE 'CAPLUS' ENTERED AT 18:53:23 ON 07 MAR 2008

FILE COVERS 1907 - 7 Mar 2008 VOL 148 ISS 11
FILE LAST UPDATED: 6 Mar 2008 (20080306/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l8
L10 1 L8

=> d ibib abs hitstr

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:493602 CAPLUS Full-text
DOCUMENT NUMBER: 143:43764
TITLE: Preparation of substituted benzothiophenes as vitamin D receptor modulators
INVENTOR(S): Lu, Jianliang; Ma, Tainwei; Nagpal, Sunil; Shen, Quanrong; Warshawsky, Alan M.; Yee, Ying Kwong; Rupp, Michael John
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 308 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051940	A2	20050609	WO 2004-US37181	20041116
WO 2005051940	A3	20050811		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2544522	A1	20050609	CA 2004-2544522	20041116
EP 1687292	A2	20060809	EP 2004-819516	20041116
EP 1687292	B1	20070822		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007512329	T	20070517	JP 2006-541233	20041116
AT 370941	T	20070915	AT 2004-819516	20041116

US 2007149810 A1 20070628 US 2006-579564 20060512
PRIORITY APPLN. INFO.: US 2003-523600P P 20031120
WO 2004-US37181 W 20041116
OTHER SOURCE(S): MARPAT 143:43764
GI



I



II

AB Title compds. I [R, R' = alkyl, fluoroalkyl, etc.; R5, R2 = H, halo, alkyl, fluoroalkyl, etc.; R4, R3, R1 = H, halo, alkyl, fluoroalkyl, etc.; X, Y, M = divalent linking groups; Z2 = branched alkyl, 3-methyl-3-hydroxypentyl, etc.; Z1 = alk(en)yloxy, cycloalkoxy, etc.] are prepared For instance, II is prepared in 5 steps from 2-fluoro-4-iodo-3- trimethylsilanylbenzaldehyde, mercaptoacetic acid, ethylmagnesium bromide, 3-pentanone, o-cresol and 1-bromopinacolone. II has an EC50 = 234 nM in a vitamin D receptor assay. I are less hypercalcemic than 1α,25-dihydroxy vitamin D3 and are useful for the treatment of bone disease and psoriasis.

IT 853600-60-9P 853600-62-1P 853600-70-1P
853600-72-3P 853600-75-6P 853600-80-3P
853600-82-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted benzothiophenes as vitamin D receptor modulators)

RN 853600-60-9 CAPLUS

CN Benzo[b]thiophene-6-carboxylic acid, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]- (CA INDEX NAME)



RN 853600-62-1 CAPLUS
CN Benzo[b]thiophene-6-carboxamide, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-N,N-dimethyl- (CA INDEX NAME)



RN 853600-70-1 CAPLUS
CN Benzo[b]thiophene-5-carboxylic acid, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]- (CA INDEX NAME)



RN 853600-72-3 CAPLUS
CN Glycine, N-[[2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]benzo[b]thien-5-yl]carbonyl]- (CA INDEX NAME)



RN 853600-75-6 CAPLUS
CN Benzo[b]thiophene-6-carboxylic acid, 2-[1-ethyl-1-[4-(2-ethyl-2-hydroxybutoxy)-3-methylphenyl]propyl]- (CA INDEX NAME)



RN 853600-80-3 CAPLUS
CN D-Alanine, N-[[2-[1-ethyl-1-[4-(2-ethyl-2-hydroxybutoxy)-3-methylphenyl]propyl]benzo[b]thien-6-yl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 853600-82-5 CAPLUS
CN L-Alanine, N-[[2-[1-ethyl-1-[4-(2-ethyl-2-hydroxybutoxy)-3-methylphenyl]propyl]benzo[b]thien-6-yl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 853600-61-0P 853600-63-2P 853600-64-3P
853600-65-4P 853600-71-2P 853600-73-4P
853600-74-5P 853600-77-8P 853600-78-9P
853600-79-0P 853600-81-4P 853600-83-6P
853600-84-7P 853600-85-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted benzothiophenes as vitamin D receptor modulators)

RN 853600-61-0 CAPLUS
CN Benzo[b]thiophene-6-carboxylic acid, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]- (CA INDEX NAME)



RN 853600-63-2 CAPLUS
CN Benzo[b]thiophene-6-carboxamide, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-N,N-dimethyl- (CA INDEX NAME)



RN 853600-64-3 CAPLUS
CN Glycine, N-[[2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]benzo[b]thien-6-yl]carbonyl]- (CA INDEX NAME)



RN 853600-65-4 CAPLUS
CN Glycine, N-[[2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]benzo[b]thien-6-yl]carbonyl]- (CA INDEX NAME)



RN 853600-71-2 CAPLUS
CN Benzo[b]thiophene-5-carboxylic acid, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]- (CA INDEX NAME)



RN 853600-73-4 CAPLUS
CN Glycine, N-[[2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]benzo[b]thien-5-yl]carbonyl]- (CA INDEX NAME)



RN 853600-74-5 CAPLUS
CN Benzo[b]thiophene-5-carboxamide, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-N,N-dimethyl- (CA INDEX NAME)



RN 853600-77-8 CAPLUS
CN 2-Butanone, 1-[4-[1-ethyl-1-[5-[(methylsulfonyl)oxy]benzo[b]thien-2-yl]propyl]-2-methylphenoxy]-3,3-dimethyl- (CA INDEX NAME)



RN 853600-78-9 CAPLUS
CN Benzo[b]thiophene-6-carboxylic acid, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-, (+)- (CA INDEX NAME)

Rotation (+).



RN 853600-79-0 CAPLUS
CN Benzo[b]thiophene-6-carboxylic acid, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 853600-81-4 CAPLUS
CN D-Alanine, N-[[2-[1-ethyl-1-[4-(2-ethyl-2-hydroxybutoxy)-3-methylphenyl]propyl]benzo[b]thien-6-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 853600-83-6 CAPLUS
CN L-Alanine, N-[[2-[1-ethyl-1-[4-(2-ethyl-2-hydroxybutoxy)-3-methylphenyl]propyl]benzo[b]thien-6-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 853600-84-7 CAPLUS
CN Alanine, N-[[2-[1-ethyl-1-[4-(2-ethyl-2-hydroxybutoxy)-3-methylphenyl]propyl]benzo[b]thien-6-yl]carbonyl]-2-methyl-, methyl ester (CA INDEX NAME)



RN 853600-85-8 CAPLUS
CN Alanine, N-[[2-[1-ethyl-1-[4-(2-ethyl-2-hydroxybutoxy)-3-methylphenyl]propyl]benzo[b]thien-6-yl]carbonyl]-2-methyl- (CA INDEX NAME)



IT 853601-14-6P 853601-20-4P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted benzothiophenes as vitamin D receptor modulators)

RN 853601-14-6 CAPLUS
CN Benzo[b]thiophene-6-carboxylic acid, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-, methyl ester, (+)- (CA INDEX NAME)

Rotation (+).



RN 853601-20-4 CAPLUS
CN Benzo[b]thiophene-6-carboxylic acid, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-, methyl ester, (-)- (CA INDEX NAME)

Rotation (-).



IT 853601-15-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted benzothiophenes as vitamin D receptor modulators)
RN 853601-15-7 CAPLUS
CN Phenol, 4-[1-ethyl-1-(6-methoxybenzo[b]thien-2-yl)propyl]-2-methyl- (CA INDEX NAME)



IT 853600-91-6P 853600-92-7P 853600-93-8P
853601-03-3P 853601-05-5P 853601-06-6P
853601-07-7P 853601-08-8P 853601-09-9P
853601-10-2P 853601-11-3P 853601-12-4P
853601-13-5P 853601-16-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted benzothiophenes as vitamin D receptor modulators)
RN 853600-91-6 CAPLUS
CN Benzo[b]thiophene-6-carboxylic acid, 2-[1-ethyl-1-(4-hydroxy-3-methylphenyl)propyl]- (CA INDEX NAME)



RN 853600-92-7 CAPLUS
CN Benzo[b]thiophene-6-carboxylic acid, 2-[1-ethyl-1-(4-hydroxy-3-methylphenyl)propyl]-, methyl ester (CA INDEX NAME)



RN 853600-93-8 CAPLUS
CN Benzo[b]thiophene-6-carboxylic acid, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-, methyl ester (CA INDEX NAME)



RN 853601-03-3 CAPLUS
CN Phenol, 4-[1-ethyl-1-(5-methoxybenzo[b]thien-2-yl)propyl]-2-methyl- (CA INDEX NAME)



RN 853601-05-5 CAPLUS
CN 2-Butanone, 1-[4-[1-ethyl-1-(5-methoxybenzo[b]thien-2-yl)propyl]-2-methylphenoxy]-3,3-dimethyl- (CA INDEX NAME)



RN 853601-06-6 CAPLUS
CN 2-Butanone, 1-[4-[1-ethyl-1-(5-hydroxybenzo[b]thien-2-yl)propyl]-2-methylphenoxy]-3,3-dimethyl- (CA INDEX NAME)



RN 853601-07-7 CAPLUS
CN Methanesulfonic acid, trifluoro-, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]benzo[b]thiophene-5-yl ester (9CI) (CA INDEX NAME)



RN 853601-08-8 CAPLUS
CN Benzo[b]thiophene-5-carboxylic acid, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-, methyl ester (CA INDEX NAME)



RN 853601-09-9 CAPLUS
CN 3-Pentanol, 3-[[4-[1-ethyl-1-(6-methoxybenzo[b]thien-2-yl)propyl]-2-methylphenoxy]methyl]- (CA INDEX NAME)



RN 853601-10-2 CAPLUS

CN Benzo[b]thiophene-6-ol, 2-[1-ethyl-1-[4-(2-ethyl-2-hydroxybutoxy)-3-methylphenyl]propyl]- (CA INDEX NAME)



RN 853601-11-3 CAPLUS
CN Methanesulfonic acid, trifluoro-, 2-[1-ethyl-1-[4-(2-ethyl-2-hydroxybutoxy)-3-methylphenyl]propyl]benzo[b]thiophene-6-yl ester (9CI) (CA INDEX NAME)



RN 853601-12-4 CAPLUS
CN Benzo[b]thiophene-6-carboxylic acid, 2-[1-ethyl-1-[4-(2-ethyl-2-hydroxybutoxy)-3-methylphenyl]propyl]-, methyl ester (CA INDEX NAME)



RN 853601-13-5 CAPLUS
CN Benzo[b]thiophene-6-carboxylic acid, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-, methyl ester (CA INDEX NAME)



RN 853601-16-8 CAPLUS
CN Acetic acid, [4-[1-ethyl-1-(6-methoxybenzo[b]thien-2-yl)propyl]-2-

methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




```
=> s l9
L11           5 L9

=> d ibib abs hitstr 1-5

L11  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2006:216966  CAPLUS  Full-text
DOCUMENT NUMBER:          144:270168
TITLE:                    Regulating PAS domain function with foreign PAS
                          ligands
INVENTOR(S):              Gardner, Kevin H.; Amezcua, Carlos A.; Erbel, Paulus
                          J. A.; Card, Paul B.; Harper, Shannon; Rutter, Jared;
                          Bruick, Richard; McKnight, Steven L.
PATENT ASSIGNEE(S):       Board of Regents, The University of Texas System, USA
SOURCE:                   U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S.
                          Ser. No. 677,734.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   4
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 2006051829         A1    20060309    US 2005-245742          20051011
     US 6319679            B1    20011120    US 2001-770170          20010126
     US 2003059917         A1    20030327    US 2001-59962           20011119
     US 7132278            B2    20061107
     US 2005074846         A1    20050407    US 2003-677734          20031001
PRIORITY APPLN. INFO.:                       US 2001-770170      A3  20010126
                                             US 2001-59962       A1  20011119
                                             US 2003-677734      A2  20031001
AB   A functional surface binding specificity of a PAS domain, wherein the PAS
     domain is predetd., prefolded in its native state, and comprises a hydrophobic
     core that has no NMR-apparent a priori formed ligand cavity, is changed by (a)
     introducing into the hydrophobic core of the PAS domain a foreign ligand of
     the PAS domain; and (b) detecting a change in the functional surface binding
     specificity of the PAS domain.  The PAS domain is part of PAS kinase.
IT   877820-07-0
     RL: BSU (Biological study, unclassified); CST (Combinatorial study,
     unclassified); BIOL (Biological study); CMBI (Combinatorial study)
        (regulating PAS domain function with foreign PAS ligands)
RN   877820-07-0  CAPLUS
CN   Phenol, 4-[1-(2-benzofuranyl)-1-methylethyl]-  (CA INDEX NAME)
```



L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:490363 CAPLUS Full-text
DOCUMENT NUMBER: 143:43763
TITLE: Preparation of substituted benzofuran vitamin d receptor modulators
INVENTOR(S): Lu, Jianliang; Ma, Tianwei; Nagpal, Sunil; Shen, Quanrong; Warshawsky, Alan M.; Ochoada, Jason Matthew; Yee, Ying Kwong
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051938	A1	20050609	WO 2004-US35529	20041116
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2544857	A1	20050609	CA 2004-2544857	20041116
EP 1687289	A1	20060809	EP 2004-800486	20041116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007512327	T	20070517	JP 2006-541192	20041116
US 2007106095	A1	20070510	US 2006-579563	20060512

PRIORITY APPLN. INFO.: US 2003-523905P P 20031120
WO 2004-US35529 W 20041116

OTHER SOURCE(S): MARPAT 143:43763
GI



I



II

AB Title compds. I [R, R' = alkyl, fluoroalkyl, etc.; Rp3, Rb = H, halo, alkyl, etc.; Rp, RF3, Rb' = H, halo alkyl, fluoroalkyl, etc.; Lp1, Lp2, Lfb = divalent linking groups; Zp = alkyl, 3-methyl-3-hydroxypentyl, etc.; Zfb = alkoxy, alkenyloxy, cycloalkoxy, etc.] are prepared For instance, II is prepared in 5 steps from 5-bromo-2-hydroxybenzaldehyde, bromoacetate, ethylmagnesium bromide, o-cresol and 1-bromopinacolone. In an osteocalcin promotor assay (marker for osteoporosis), II has EC50 = 1 nM. I are exhibit vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25-dihydroxy vitamin D3 and are useful for treating bone disease and psoriasis.

IT 853598-34-2P 853598-36-4P 853598-38-6P
853598-39-7P 853598-42-2P 853598-43-3P
853598-44-4P 853598-46-6P 853598-49-9P
853598-50-2P 853598-71-7P 853598-85-3P
853598-86-4P 853598-87-5P 853598-88-6P
853598-89-7P 853598-90-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted benzofuran vitamin d receptor modulators)

RN 853598-34-2 CAPLUS

CN 5-Benzofurancarboxylic acid, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-, methyl ester (CA INDEX NAME)



RN 853598-36-4 CAPLUS

CN 5-Benzofurancarboxylic acid, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-, methyl ester (CA INDEX NAME)



RN 853598-38-6 CAPLUS
CN 5-Benzofurancarboxamide, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-N,N-dimethyl- (CA INDEX NAME)



RN 853598-39-7 CAPLUS
CN Glycine, N-[[2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-5-benzofuranyl]carbonyl]- (CA INDEX NAME)



RN 853598-42-2 CAPLUS
CN Glycine, N-[[2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-5-benzofuranyl]carbonyl]-N-methyl- (CA INDEX NAME)



RN 853598-43-3 CAPLUS
CN Alanine, N-[[2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-5-benzofuranyl]carbonyl]-2-methyl- (CA INDEX NAME)



RN 853598-44-4 CAPLUS
CN 5-Benzofurancarboxamide, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)



RN 853598-46-6 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-[4-[[2-(1,1-dimethylethyl)-1,3-dioxolan-2-yl]methoxy]-3-methylphenyl]-1-ethylpropyl]-, methyl ester (CA INDEX NAME)



RN 853598-49-9 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-(1-methylethyl)phenyl]-1-ethylpropyl]- (CA INDEX NAME)



RN 853598-50-2 CAPLUS
CN 6-Benzofurancarboxylic acid, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]- (CA INDEX NAME)



RN 853598-71-7 CAPLUS
CN 2-Butanone, 1-[4-[1-ethyl-1-[6-[(methylsulfonyl)oxy]-2-benzofuranyl]propyl]-2-methylphenoxy]-3,3-dimethyl- (CA INDEX NAME)



RN 853598-85-3 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-ethyl-1-[4-[(2R)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 853598-86-4 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-ethyl-1-[4-[(2S)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 853598-87-5 CAPLUS
CN 6-Benzofurancarboxylic acid, 2-[1-ethyl-1-[4-[(2R)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 853598-88-6 CAPLUS
CN 6-Benzofurancarboxylic acid, 2-[1-ethyl-1-[4-[(2S)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 853598-89-7 CAPLUS
CN Glycine, N-[[2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-(1-methylethyl)phenyl]-1-ethylpropyl]-5-benzofuranyl]carbonyl]- (CA INDEX NAME)



RN 853598-90-0 CAPLUS
CN Glycine, N-[[2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-ethylphenyl]-1-ethylpropyl]-5-benzofuranyl]carbonyl]-N-methyl- (CA INDEX NAME)



IT 853598-35-3P 853598-37-5P 853598-40-0P
853598-45-5P 853598-47-7P 853598-48-8P
853598-51-3P 853598-52-4P 853598-72-8P
853598-73-9P 853598-74-0P 853598-80-8P
853598-81-9P 853598-94-4P 853598-95-5P
853598-96-6P 853598-97-7P 853598-98-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted benzofuran vitamin d receptor modulators)

RN 853598-35-3 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]- (CA INDEX NAME)



RN 853598-37-5 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]- (CA INDEX NAME)



RN 853598-40-0 CAPLUS
CN Glycine, N-[[2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-5-benzofuranyl]carbonyl]- (CA INDEX NAME)



RN 853598-45-5 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-ethylphenyl]-1-ethylpropyl]- (CA INDEX NAME)



RN 853598-47-7 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-[4-[[2-(1,1-dimethylethyl)-1,3-dioxolan-2-yl]methoxy]-3-methylphenyl]-1-ethylpropyl]- (CA INDEX NAME)



RN 853598-48-8 CAPLUS
CN Glycine, N-[[2-[1-[4-[[2-(1,1-dimethylethyl)-1,3-dioxolan-2-yl]methoxy]-3-methylphenyl]-1-ethylpropyl]-5-benzofuranyl]carbonyl]- (CA INDEX NAME)



RN 853598-51-3 CAPLUS
CN 6-Benzofurancarboxylic acid, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]- (CA INDEX NAME)



RN 853598-52-4 CAPLUS
CN Glycine, N-[[2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-6-benzofuranyl]carbonyl]- (CA INDEX NAME)



RN 853598-72-8 CAPLUS
CN 6-Benzofuranol, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-, 6-(methanesulfonate) (9CI) (CA INDEX NAME)



RN 853598-73-9 CAPLUS
CN Alanine, N-[[2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-5-benzofuranyl]carbonyl]-2-methyl- (CA INDEX NAME)



RN 853598-74-0 CAPLUS
CN Glycine, N-[[2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-5-benzofuranyl]carbonyl]-N-methyl- (CA INDEX NAME)



RN 853598-80-8 CAPLUS
CN 5-Benzofuranol, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-, 5-(methanesulfonate) (9CI) (CA INDEX NAME)



RN 853598-81-9 CAPLUS
CN 2-Butanone, 1-[4-[1-ethyl-1-[5-[(methylsulfonyl)methyl]-2-benzofuranyl]propyl]-2-methylphenoxy]-3,3-dimethyl- (CA INDEX NAME)



RN 853598-94-4 CAPLUS
CN Glycine, N-[[2-[1-ethyl-1-[3-ethyl-4-(2-hydroxy-3,3-dimethylbutoxy)phenyl]propyl]-5-benzofuranyl]carbonyl]-N-methyl- (CA INDEX NAME)



RN 853598-95-5 CAPLUS
CN Glycine, N-[[2-[1-ethyl-1-[4-[(2R)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl]propyl]-6-benzofuranyl]carbonyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 853598-96-6 CAPLUS
CN Glycine, N-[[2-[1-ethyl-1-[4-[(2S)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl]propyl]-6-benzofuranyl]carbonyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 853598-97-7 CAPLUS
CN Glycine, N-[[2-[1-ethyl-1-[4-[(2R)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl]propyl]-5-benzofuranyl]carbonyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 853598-98-8 CAPLUS
CN Glycine, N-[[2-[1-ethyl-1-[4-[(2S)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl]propyl]-5-benzofuranyl]carbonyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 853599-80-1 853599-82-3 853599-84-5
853599-85-6 853599-88-9 853599-89-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of substituted benzofuran vitamin d receptor modulators)

RN 853599-80-1 CAPLUS
CN Alanine, N-[[2-[1-ethyl-1-[4-[(2S)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl]propyl]-5-benzofuranyl]carbonyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853599-82-3 CAPLUS
CN 5-Benzofuranol, 2-[1-ethyl-1-[4-[(2S)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl]propyl]-, 5-(methanesulfonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 853599-84-5 CAPLUS
CN Glycine, N-[[2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-(1-methylethyl)phenyl]propyl]-5-benzofuranyl]carbonyl]-N-methyl- (CA INDEX NAME)



RN 853599-85-6 CAPLUS
CN Glycine, N-[[2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-6-benzofuranyl]carbonyl]-N-methyl- (CA INDEX NAME)



RN 853599-88-9 CAPLUS
CN 5-Benzofurancarboxamide, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-N,N-dimethyl- (CA INDEX NAME)



RN 853599-89-0 CAPLUS

CN 5-Benzofurancarboxamide, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)



IT 853599-61-8P 853599-63-0P 853599-64-1P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted benzofuran vitamin d receptor modulators)

RN 853599-61-8 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-ethyl-1-[4-[(2S)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl]propyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 853599-63-0 CAPLUS
CN 6-Benzofurancarboxylic acid, 2-[1-ethyl-1-[4-[(2R)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl]propyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 853599-64-1 CAPLUS
CN 6-Benzofurancarboxylic acid, 2-[1-ethyl-1-[4-[(2S)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl]propyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 853599-17-4P 853599-18-5P 853599-19-6P
853599-20-9P 853599-21-0P 853599-23-2P
853599-24-3P 853599-25-4P 853599-26-5P
853599-27-6P 853599-47-0P 853599-48-1P
853599-49-2P 853599-50-5P 853599-51-6P
853599-52-7P 853599-53-8P 853599-60-7P
853599-62-9P 853599-66-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted benzofuran vitamin d receptor modulators)

RN 853599-17-4 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-ethyl-1-(4-hydroxy-3-methylphenyl)propyl]-, methyl ester (CA INDEX NAME)



RN 853599-18-5 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-ethyl-1-(3-ethyl-4-hydroxyphenyl)propyl]-, methyl ester (CA INDEX NAME)



RN 853599-19-6 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-ethylphenyl]-1-ethylpropyl]-, methyl ester (CA INDEX NAME)



RN 853599-20-9 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-ethyl-1-[4-hydroxy-3-(1-methylethyl)phenyl]propyl]-, methyl ester (CA INDEX NAME)



RN 853599-21-0 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-(1-methylethyl)phenyl]-1-ethylpropyl]-, methyl ester (CA INDEX NAME)



RN 853599-23-2 CAPLUS
CN Phenol, 4-[1-ethyl-1-[6-(phenylmethoxy)-2-benzofuranyl]propyl]-2-methyl- (CA INDEX NAME)



RN 853599-24-3 CAPLUS

CN 2-Butanone, 1-[4-[1-ethyl-1-[6-(phenylmethoxy)-2-benzofuranyl]propyl]-2-methylphenoxy]-3,3-dimethyl- (CA INDEX NAME)



RN 853599-25-4 CAPLUS
CN 2-Butanone, 1-[4-[1-ethyl-1-(6-hydroxy-2-benzofuranyl)propyl]-2-methylphenoxy]-3,3-dimethyl- (CA INDEX NAME)



RN 853599-26-5 CAPLUS
CN Methanesulfonic acid, trifluoro-, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-6-benzofuranyl ester (9CI) (CA INDEX NAME)



RN 853599-27-6 CAPLUS
CN 6-Benzofurancarboxylic acid, 2-[1-[4-(3,3-dimethyl-2-oxobutoxy)-3-methylphenyl]-1-ethylpropyl]-, methyl ester (CA INDEX NAME)



RN 853599-47-0 CAPLUS
CN Phenol, 4-[1-ethyl-1-[5-(phenylmethoxy)-2-benzofuranyl]propyl]-2-methyl- (CA INDEX NAME)



RN 853599-48-1 CAPLUS
CN 2-Butanone, 1-[4-[1-ethyl-1-[5-(phenylmethoxy)-2-benzofuranyl]propyl]-2-methylphenoxy]-3,3-dimethyl- (CA INDEX NAME)



RN 853599-49-2 CAPLUS
CN 2-Butanone, 1-[4-[1-ethyl-1-(5-hydroxy-2-benzofuranyl)propyl]-2-methylphenoxy]-3,3-dimethyl- (CA INDEX NAME)



RN 853599-50-5 CAPLUS
CN 2-Butanone, 1-[4-[1-ethyl-1-[5-[(methylsulfonyl)oxy]-2-benzofuranyl]propyl]-2-methylphenoxy]-3,3-dimethyl- (CA INDEX NAME)



RN 853599-51-6 CAPLUS

CN 5-Benzofuranmethanol, 2-[1-ethyl-1-(4-hydroxy-3-methylphenyl)propyl]- (CA INDEX NAME)



RN 853599-52-7 CAPLUS
CN 2-Butanone, 1-[4-[1-ethyl-1-[5-(hydroxymethyl)-2-benzofuranyl]propyl]-2-methylphenoxy]-3,3-dimethyl- (CA INDEX NAME)



RN 853599-53-8 CAPLUS
CN 2-Butanone, 1-[4-[1-ethyl-1-[5-[(methylthio)methyl]-2-benzofuranyl]propyl]-2-methylphenoxy]-3,3-dimethyl- (CA INDEX NAME)



RN 853599-60-7 CAPLUS
CN 5-Benzofurancarboxylic acid, 2-[1-ethyl-1-[4-[(2R)-2-hydroxy-3,3-dimethylbutoxy]-3-methylphenyl]propyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 853599-62-9 CAPLUS
CN 6-Benzofurancarboxylic acid, 2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-, methyl ester (CA INDEX NAME)



RN 853599-66-3 CAPLUS
CN Glycine, N-[[2-[1-ethyl-1-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]propyl]-6-benzofuranyl]carbonyl]-N-methyl-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:439794 CAPLUS Full-text
DOCUMENT NUMBER: 107:39794
TITLE: Preparation of hypoglycemic 2,4-thiazolidinediones
INVENTOR(S): Eggler, James F.; Holland, Gerald F.; Johnson, Michael Ross; Volkmann, Robert A.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8607056	A1	19861204	WO 1985-US962	19850521
W: FI, HU, NO, SU, US				
HU 45247	A2	19880628	HU 1985-3021	19850521
HU 210339	B	19950328		
EP 207605	A1	19870107	EP 1986-303648	19860514
EP 207605	B1	19900207		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 50256	T	19900215	AT 1986-303648	19860514
CA 1279320	C	19910122	CA 1986-509336	19860516

IL 78831	A	19901129	IL 1986-78831		19860519
DK 8602335	A	19861122	DK 1986-2335		19860520
AU 8657580	A	19870108	AU 1986-57580		19860520
AU 560179	B2	19870402			
ES 555147	A1	19870716	ES 1986-555147		19860520
ZA 8603762	A	19880525	ZA 1986-3762		19860520
DD 261154	A5	19881019	DD 1986-290390		19860520
JP 61271287	A	19861201	JP 1986-117127		19860521
JP 05086953	B	19931214			
CN 86104075	A	19870311	CN 1986-104075		19860521
CN 1007248	B	19900321			
PL 147479	B1	19890630	PL 1986-259633		19860521
US 4703052	A	19871027	US 1986-10081		19861229
FI 8700219	A	19870120	FI 1987-219		19870120
FI 89268	B	19930531			
FI 89268	C	19930910			
NO 8700241	A	19870320	NO 1987-241		19870120
NO 166448	B	19910415			
NO 166448	C	19910724			
SU 1556540	A3	19900407	SU 1987-4028918		19870120
AU 8775074	A	19871015	AU 1987-75074		19870702
AU 583991	B2	19890511			
IL 83214	A	19910718	IL 1987-83214		19870716
ES 557634	A1	19880716	ES 1987-557634		19870727
ES 557634	A5	19880812			

PRIORITY APPLN. INFO.:

WO 1985-US962	W	19850521
EP 1986-303648	A	19860514
IL 1986-78831	A	19860519

OTHER SOURCE(S): CASREACT 107:39794; MARPAT 107:39794

GI



I



II

AB The title compds. [I; R = H; (R)2 = bond; R1 = H, pyridyl, furyl, thienyl, naphthyl, (un)substituted alkyl, cycloalkyl, Ph, etc.; R2 = H, Me; R3 = H, alkyl, PhCH2, (un)substituted Ph; R4 = H; R1R2, R2R3, R3R4 = alkylene; R5 = H, Me, Et; X = O, S, SO, SO2, etc.; n = 0-2] were prepared as hypoglycemic agents (no data). 2-HOC6H4CHO and BrCH2COPh were refluxed in DMF to give 2-benzoylbenzofuran, which was hydrogenated over Pd/C to give 2-benzyl-2,3-dihydrobenzofuran. The latter was formylated by treatment with TiCl4 and Cl2CHOMe in CH2Cl2 at 0-5° and the resulting 5-formyl derivative was heated at 140° with 2,4-thiazolidinedione and NaOAc to give (benzofuranylmethylene)thiazolidinedione II.

IT 109210-31-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reduction of)
RN 109210-31-3 CAPLUS
CN Benzofuran, 2-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:455708 CAPLUS Full-text
DOCUMENT NUMBER: 91:55708
ORIGINAL REFERENCE NO.: 91:9019a,9022a
TITLE: Carbon-13 NMR spectra of some furocoumarins
AUTHOR(S): Bose, Ajay K.; Fujiwara, H.; Kamat, Vinayak S.; Trivedi, Girish K.; Bhattacharyya, Sasanka C.
CORPORATE SOURCE: Dep. Chem. Chem. Eng., Stevens Inst. Technol., Hoboken, NJ, USA
SOURCE: Tetrahedron (1979), 35(1), 13-16
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The 13C NMR spectra of the naturally occurring furocoumarins I (R = H, CMe2OH) and derivs. I (R = CHMe2, CMe2Ph, CMe2C6H4OMe-4) were studied.
IT 55710-65-1P 55710-66-2P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and carbon-13 NMR of)
RN 55710-65-1 CAPLUS
CN 2H-Furo[2,3-h]-1-benzopyran-2-one, 8-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 55710-66-2 CAPLUS
CN 2H-Furo[2,3-h]-1-benzopyran-2-one, 8-[1-(4-methoxyphenyl)-1-methylethyl]- (CA INDEX NAME)



L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:170745 CAPLUS Full-text
DOCUMENT NUMBER: 82:170745
ORIGINAL REFERENCE NO.: 82:27281a,27284a
TITLE: Structures of two dimers formed from oroselol with acids
AUTHOR(S): Kamat, Vinayak S.; Audichya, Thakur D.; Trivedi, Girish K.; Bhattacharyya, Sasanka C.
CORPORATE SOURCE: Dep. Chem., Indian Inst. Technol., Bombay, India
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1975), (3), 204-8
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Addnl date considered in abstracting and indexing are available from a source cited in the original document. Oroselol (I), a furocoumarin extracted from Selinium vaginatum, with acid formed dimers II and III via a carbonium ion and subsequent condensation with oroselone (IV). This mechanism was supported by the formation of V-VII from I in the presence of Lewis acids.
IT 55710-65-1P 55710-66-2P 55710-67-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 55710-65-1 CAPLUS
CN 2H-Furo[2,3-h]-1-benzopyran-2-one, 8-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 55710-66-2 CAPLUS
CN 2H-Furo[2,3-h]-1-benzopyran-2-one, 8-[1-(4-methoxyphenyl)-1-methylethyl]-

(CA INDEX NAME)



RN 55710-67-3 CAPLUS
CN 2H-Furo[2,3-h]-1-benzopyran-2-one, 8-[1-(4-ethoxyphenyl)-1-methylethyl]-
(CA INDEX NAME)



=> logoff h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	34.14	264.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.80	-4.80

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 18:55:07 ON 07 MAR 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptansc1625

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 18:58:38 ON 07 MAR 2008
FILE 'CAPLUS' ENTERED AT 18:58:38 ON 07 MAR 2008

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	34.14	264.47

```
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -4.80      -4.80

=> d his

     (FILE 'HOME' ENTERED AT 18:40:05 ON 07 MAR 2008)

     FILE 'REGISTRY' ENTERED AT 18:40:17 ON 07 MAR 2008
L1              STRUCTURE UPLOADED
L2            3 S SSS SAM L1
L3              STRUCTURE UPLOADED
L4            0 S SSS SAM L3
L5          107 S SSS FULL L3
                SAVE L5 LU10579564/A
L6              STRUCTURE UPLOADED
L7            0 S SSS L6 SAM SUB=L5
L8           38 S SSS L6 FULL SUB=L5
L9           69 S L5 NOT L8

     FILE 'CAPLUS' ENTERED AT 18:53:23 ON 07 MAR 2008
L10           1 S L8
L11           5 S L9

=> activate LU10579564/A
ANSWER SET WAS CREATED IN FILE 'REGISTRY'.
An answer set can be activated only in the same file in
which the search was done.  Use the FILE command to switch
to the correct file.  Then enter ACTIVATE.
ACTIVATE QUERY ONLY? (Y)/N:y
L12             STR
L13             QUE  ABB=ON  PLU=ON  L12

=> delete LU10579564/A
DELETE LU10579564/A? (Y)/N:y
LU10579564/A DELETED

=> save temp l5 LU10579564/A
ANSWER SET NOT SAVED.
THE ANSWER SET WAS CREATED IN FILE 'REGISTRY'.
USE THE FILE COMMAND TO CHANGE TO THE CORRECT FILE.
Answer sets must be saved in the same file in which they were
created.

=> fil reg
COST IN U.S. DOLLARS                             SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   35.58     265.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -4.80      -4.80

FILE 'REGISTRY' ENTERED AT 19:00:43 ON 07 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.
```

STRUCTURE FILE UPDATES: 6 MAR 2008 HIGHEST RN 1006950-27-1
DICTIONARY FILE UPDATES: 6 MAR 2008 HIGHEST RN 1006950-27-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> activate LU10579564/A
'LU10579564/A' NOT FOUND
The name that you entered was not found in the list of saved queries,
answer sets, or L# lists for this loginid. Enter "DISPLAY SAVED" at
an arrow prompt (=>) to see a list of all saved queries, answer sets,
and L# lists for this loginid. To see the names of all SDI profiles,
enter "DISPLAY SAVED/S". To see the names of all BATCH search
requests, enter "DISPLAY SAVED/B".

=> save temp l5 LU10579564/A
ANSWER SET L5 HAS BEEN SAVED AS 'LU10579564/A'

=> logoff y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.46	266.37

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.80

STN INTERNATIONAL LOGOFF AT 19:01:21 ON 07 MAR 2008